Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.07.2019 | Case report

Vedolizumab

Prostate adenocarcinoma: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Amiot A, et al. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary Pharmacology and Therapeutics 50: 40-53, No. 1, Jul 2019. Available from: URL: http://doi.org/10.1111/apt.15294 - France Amiot A, et al. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary Pharmacology and Therapeutics 50: 40-53, No. 1, Jul 2019. Available from: URL: http://​doi.​org/​10.​1111/​apt.​15294 - France
Metadaten
Titel
Vedolizumab
Prostate adenocarcinoma: case report
Publikationsdatum
01.07.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-64734-0

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Dexamfetamine

Case report

Nivolumab